S&P Capital IQ Equity Analyst Herman Saftlas joins Brian Egli, S&P Capital IQ Editorial, to discuss diabetes and where investment opportunities might lie with companies that are fighting this disease such as Johnson & Johnson (JNJ) . To read this and all Trends & Ideas content, please visit www.marketscope.com.